Miromatrix straddles the line between biotech and medtech. The start-up is developing a line of “ghost organs” that can be used in humans. The technology is moving fast, and Ross hopes to have clinical trials up and running by the end of 2020. The future is here. Also, I’ll announce a keynote speaker for the May 30 Medtech Conference.
Jeff Ross, PhD
Dr. Ross brings more than 20 years of biomedical research, management and regulatory experience in regenerative medicine, biologics, and medical devices to Miromatrix including concept development, preclinical, clinical, manufacturing, and commercialization. He has held various technical and management positions at Guidant, Athersys and SurModics. Since coming to Miromatrix in 2010 he has been pivotal in the development, manufacturing and regulatory clearance of the innovative MIROMESH and MIRODERM product lines. He has spearheaded development, global patent strategy, and fundraising for the revolutionary whole organ transplant program and its key decellularization technology. Dr. Ross has over 30 patents along with scientific publications in Nature and other peer-reviewed journals. He holds a Master’s degree in Biomedical Engineering and a Ph.D. in Molecular, Cellular and Developmental Biology from the University of Minnesota.
Meet Our Host
A follower and fan of medtech for nearly two decades, Tom Salemi is the former bureau chief, venture capital, at Elsevier Business Intelligence, where he oversaw coverage of venture investments in medtech.